Health

The new hydrogel injection provides patients with enhanced mobility without surgery

New injection treatment for knee osteoarthritis using non-biodegradable hydrogel technology – Arthrosamid® – Officially launched on the UK market at 21 of the British Orthopedic Association (BOA) Annual MeetingNS-twenty fourNS September 2021.

Pioneered by Contura International Ltd, [international manufacturers of therapeutic hydrogels], Arthrosamid® Unmet clinical for effective, long-acting, safe and minimally invasive treatments to provide an alternative to current therapies and reduce pain associated with osteoarthritis of the knee (OA) Meet your needs.

This treatment has the potential to change current care channels for managing OA, which affects approximately 8.5 million people in the United Kingdom. In the United Kingdom, one in five people over the age of 45 is affected by knee osteoarthritis, and current treatments are either short-lived or involve invasive knee replacement. Despite the large population suffering, so far there has been little innovation in the range of OA treatments offered to help patients meaningfully.

A 6 ml Arthrosamid® consisting of 2.5% cross-linked polyacrylamide and 97.5% non-pyrogenic water is injected into the joint cavity to cushion the knee and relieve pain with a single treatment. Patients can expect to see improved motility and pain relief within a few days of long-lasting effects.


Many clinical trials on Arthrosamid have been completed® Further testing in progress:

  • The prospective open-label trial “IDA” demonstrated Arthrosamid®Effective in reducing pain at 6 months, maintained at 12 months. The study, along with established safety and performance data for hydrogel technology, satisfied European regulators and granted Arthrosamid approval (CE mark).® For symptomatic treatment of patients with knee osteoarthritis. According to data published in Osteoarthritis and Cartilage in 2021, more than 70% of patients have a positive treatment experience, exceeding the clinically significant minimum difference, 6 months. Pain, stiffness, reduced mobility, and maintenance of pain and physical function. 1 year.
  • Positive results from another multicenter, randomized, controlled, 1-year clinical trial of Arthrosamid® in 238 patients with knee osteoarthritis, ROSA, will be published at the end of 2021. Pain relief one year after a single injection of Arthrosamid® and pain relief achieved with major brands of hyaluronic acid, a common treatment for the same indications. This study will follow patients for up to 5 years.

Arthrosamid® injections are currently available Network of leading orthopedists Throughout the UK, including Professor Martin Shaw Birmingham Knee and Shoulder Clinic, Professor Paul Lee 108 Harley Street And Mr. Sanji Nando, OrthTeamcentre, Manchester.

Action mode When injected into the joint lumen, Arthrosamid® integrates into the synovial tissue of the internal capsule, thickening the synovium. The non-absorbable, non-biodegradable, non-migratory properties of Arthrosamid® provide a durable cushioning of the internal capsule tissue, thereby reducing pain, reducing joint stiffness and the effects of OA. Improves the function of the receiving knee. Unlike other types of intra-articular injections, such as hyaluronic acid, which only function as a mucus supplement, Arthrosamid® is physically different because it is an integrated portion of the soft synovial tissue within the joint capsule. Much longer than older generation OA treatments such as cross-linked hyaluronic acid.

This remedy has been around for 20 years and has an interesting legacy as a veterinary product and as a remedy used by humans in a variety of conditions. A detailed understanding of the biocompatibility of hydrogels has been derived from preclinical and histological studies of goats and rabbits. In addition, over the last decade, thousands of horses with OA treated with Arthramide Vet®, a veterinary trade name hydrogel technology, have gained extensive horse medical experience.

In the meantime, a study showing that 80% of horses were lame after a single injection demonstrated a significant improvement, initially 12 months and lasting up to 24 months.

The journey to realize the potential of products to treat human joint pain is Dr. Andreas Hartcop, a pioneering consultant and rheumatologist who undertook a series of small pilot studies at his clinic in Denmark in 2010. Guided by. I was destined for knee replacement. The results were encouraging, and over time, Dr. Hartcop began treating many patients for compassionate use, with positive results.

In recent years, studies of hundreds of patients across different locations have confirmed consistent efficacy with Arthrosamid.® Further research is underway, including experts from all over Denmark, to support its role in the treatment of patients with knee osteoarthritis.

Sean Curry, an orthopedic and trauma surgeon at the London Orthopedic Clinic in King Edward VII, London, gave a presentation at a thought leadership session on Arthrosamid.® The BOA Congress explains:Osteoarthritis (OA) is the most common type of arthritis and the fastest growing disorder in the world, but scientific progress in this area has been slow and treatment options have been limited. rice field. This new injection provides patients with treatments that can not only relieve the symptoms of knee osteoarthritis, but also delay or eliminate the need for more invasive partial or complete knee arthroplasty. can do.

Rakesh Tailor, Chief Operating Officer of Contura International Ltd, commented:Twenty years after the idea of ​​investigating the use of hydrogels in human joints was first proposed after 10 years of rigorous testing, biocompatibility analysis and clinical research, Arthrosamid® was used for knee-related pain. I am happy that it is now available as a remedy. OA.

“”Discomfort caused by OA can have a significant impact on a patient’s quality of life and can make daily activities difficult. Arthrosamid for patients under the age of 70 who may be too young for knee arthroplasty® In particular, it represents a game-changing option that provides long-term pain relief and mobility without the need for surgery with a single therapeutic injection. We are excited to work with experts to establish potentially new treatment algorithms for patients suffering from knee osteoarthritis.

Medical professionals can visit to see more details and clinical evidence of this new treatment www.arthrosamid.com.. Contact the Contura Orthopedics Team for information on how to provide this treatment to patients in the clinic. enquiries@arthrosamid.com For a promise.


This article is sponsored by Contura International Ltd..

The new hydrogel injection provides patients with enhanced mobility without surgery

Source link The new hydrogel injection provides patients with enhanced mobility without surgery

Related Articles

Back to top button